HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.

AbstractImportance:
The use of high-field magnetic resonance spectroscopy (MRS) in multiple brain regions of a large population of human participants facilitates in vivo study of localized or diffusely altered brain metabolites in patients with first-episode psychosis (FEP) compared to healthy participants.
Objective:
To compare metabolite levels in 5 brain regions between patients with FEP (evaluated within 2 years of onset) and healthy controls, and to explore possible associations between targeted metabolite levels and neuropsychological test performance.
Design, Setting, and Participants:
Cross-sectional design used 7-T MRS at a research MR imaging facility in participants recruited from clinics at the Johns Hopkins Schizophrenia Center and the local population. Eighty-one patients who had received a DSM-IV diagnosis of FEP within the last 2 years and 91 healthy age-matched (but not sex-matched) volunteers participated.
Main Outcomes and Measures:
Brain metabolite levels including glutamate, glutamine, γ-aminobutyric acid (GABA), N-acetylaspartate, N-acetylaspartyl glutamate, and glutathione, as well as performance on neuropsychological tests.
Results:
The mean (SD) age of 81 patients with FEP was 22.3 (4.4) years and 57 were male, while the mean (SD) age of 91 healthy participants was 23.3 (3.9) years and 42 were male. Compared with healthy participants, patients with FEP had lower levels of glutamate (F1,162 = 8.63, P = .02), N-acetylaspartate (F1,161 = 5.93, P = .03), GABA (F1,163 = 6.38, P = .03), and glutathione (F1,162 = 4.79, P = .04) in the anterior cingulate (all P values are corrected for multiple comparisons); lower levels of N-acetylaspartate in the orbitofrontal region (F1,136 = 7.23, P = .05) and thalamus (F1,133 = 6.78, P = .03); and lower levels of glutathione in the thalamus (F1,135 = 7.57, P = .03). Among patients with FEP, N-acetylaspartate levels in the centrum semiovale white matter were significantly correlated with performance on neuropsychological tests, including processing speed (r = 0.48; P < .001), visual (r = 0.33; P = .04) and working (r = 0.38; P = .01) memory, and overall cognitive performance (r = 0.38; P = .01).
Conclusions and Relevance:
Seven-tesla MRS offers insights into biochemical changes associated with FEP and may be a useful tool for probing brain metabolism that ranges from neurotransmission to stress-associated pathways in participants with psychosis.
AuthorsAnna M Wang, Subechhya Pradhan, Jennifer M Coughlin, Aditi Trivedi, Samantha L DuBois, Jeffrey L Crawford, Thomas W Sedlak, Fredrick C Nucifora Jr, Gerald Nestadt, Leslie G Nucifora, David J Schretlen, Akira Sawa, Peter B Barker
JournalJAMA psychiatry (JAMA Psychiatry) Vol. 76 Issue 3 Pg. 314-323 (03 01 2019) ISSN: 2168-6238 [Electronic] United States
PMID30624573 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Dipeptides
  • Glutamine
  • isospaglumic acid
  • Aspartic Acid
  • Glutamic Acid
  • gamma-Aminobutyric Acid
  • N-acetylaspartate
Topics
  • Aspartic Acid (analogs & derivatives, metabolism)
  • Brain (metabolism)
  • Case-Control Studies
  • Cross-Sectional Studies
  • Dipeptides (metabolism)
  • Female
  • Glutamic Acid (metabolism)
  • Glutamine (metabolism)
  • Humans
  • Male
  • Neuropsychological Tests
  • Proton Magnetic Resonance Spectroscopy (instrumentation)
  • Psychotic Disorders (metabolism)
  • Young Adult
  • gamma-Aminobutyric Acid (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: